SILCOPHL Stock Overview
Manufactures and markets finished pharmaceutical products in Bangladesh.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Silco Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳22.30 |
| 52 Week High | ৳25.10 |
| 52 Week Low | ৳16.20 |
| Beta | 0.24 |
| 11 Month Change | 31.18% |
| 3 Month Change | 34.34% |
| 1 Year Change | -4.70% |
| 33 Year Change | -32.83% |
| 5 Year Change | -11.12% |
| Change since IPO | -2.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| SILCOPHL | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 3.7% | -2.5% | -2.6% |
| 1Y | -4.7% | -19.5% | -21.5% |
Return vs Industry: SILCOPHL exceeded the BD Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: SILCOPHL exceeded the BD Market which returned -21.5% over the past year.
Price Volatility
| SILCOPHL volatility | |
|---|---|
| SILCOPHL Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in BD Market | 7.4% |
| 10% least volatile stocks in BD Market | 3.6% |
Stable Share Price: SILCOPHL's share price has been volatile over the past 3 months.
Volatility Over Time: SILCOPHL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BD stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 311 | Md. Haque Rukan | www.silcopharma.com |
Silco Pharmaceuticals Limited manufactures and markets finished pharmaceutical products in Bangladesh. The company offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxatives, lipid lowering agents, mycolytic expectorants, and NSAIDs, as well as multi-medicines. It provides its products in various human drugs dosage forms, such as tablets, capsules, syrups, oral solids and liquids, suspension and powder for suspension, etc. The company also exports its medicines to Afghanistan, Bhutan, Myanmar, Ivory Coast, Kenya, Mauritius, Somalia, Tanzania, Uganda, and internationally.
Silco Pharmaceuticals Limited Fundamentals Summary
| SILCOPHL fundamental statistics | |
|---|---|
| Market cap | ৳2.31b |
| Earnings (TTM) | ৳42.76m |
| Revenue (TTM) | ৳421.83m |
54.1x
P/E Ratio5.5x
P/S RatioIs SILCOPHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SILCOPHL income statement (TTM) | |
|---|---|
| Revenue | ৳421.83m |
| Cost of Revenue | ৳295.37m |
| Gross Profit | ৳126.47m |
| Other Expenses | ৳83.71m |
| Earnings | ৳42.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 29.98% |
| Net Profit Margin | 10.14% |
| Debt/Equity Ratio | 0% |
How did SILCOPHL perform over the long term?
See historical performance and comparison